Auris Medical Holding (Nasdaq: EARS) reported disappointing results from a TACTT2 trial of its acute inner ear tinnitus treatment Keyzilen and reported a loss of for the second quarter. The stock price plunged $3.20 to close at $2.15.
Auris Medical's Keyzilen fails study
August 18, 2016 at 17:22 PM EDT
